Exendin agonist compounds

Details Exendin agonist compounds Exendin agonist compounds

2006-08-28

2010-12-28

Borin, Michael (Department: 1631)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

25 or more amino acid residues in defined sequence

C530S300000, C514S002600, C514S012200

Reexamination Certificate

active

07858740

ABSTRACT:
Novel exendin agonist compounds are provided. These compounds are useful in treating Type I and II diabetes and conditions which would be benefited by lower plasma glucose and delaying and/or slowing gastric emptying.

REFERENCES:
patent: 5118666 (1992-06-01), Habener
patent: 5120712 (1992-06-01), Habener
patent: 5424286 (1995-06-01), Eng
patent: 5512549 (1996-04-01), Chen
patent: 5545618 (1996-08-01), Buckley
patent: 5574008 (1996-11-01), Johnson
patent: 5686511 (1997-11-01), Bobo
patent: 5705483 (1998-01-01), Galloway et al.
patent: 5846937 (1998-12-01), Drucker
patent: 6191102 (2001-02-01), DiMarchi et al.
patent: 6767887 (2004-07-01), Hoffmann et al.
patent: WO 90/11296 (1990-04-01), None
patent: WO 91/11457 (1991-08-01), None
patent: WO 93/18786 (1993-09-01), None
patent: WO 93/25579 (1993-12-01), None
patent: WO 98/19698 (1998-05-01), None
patent: WO 98/30231 (1998-07-01), None
patent: WO 98/05351 (1998-12-01), None
patent: WO 99/07404 (1999-02-01), None
The Bachem internet website, (product No. U-1160, downloaded Dec. 13, 2007).
Chen et al, The Journal of Biological Chemistry, 272(7):4108-4115 (Feb. 14, 1997).
Nielsen et al, Current Opinion in Investigational Drugs, 4(4):401-405 (2003).
Nielsen et al, Regulatory Peptides, 117:77-88 (2004).
Byrne et al., Diabet. Med. 13(1):854-860 (1996).
Conn & Stumpf, Outlines in Biochemistry, Third Edition, John Wiley & Sons, pp. 69-74 (1972).
Dupre et al, Diabetes, 44:626-630 (1995).
Gutniak et al, The New England Journal of Medicine, 326:1316-1322 (1992).
Harris, Gut, Supplement 3, pp. S1-S4 (1994).
Hunt et al, British Medical Journal, 4(5576):386-387 (1967).
Nauk, Diabetic Medicine, 13:S39-S43 (1996).
Neidigh et al, Biochemistry, 40(44):13188-13200 (2001).
EPO Communication of Notice of Opposition and Opposition to European Patent No. 1 019 077 by Strawman Limited (EPO Communication dated Sep. 5, 2008).
Adelhorst, K., et al.,“Structure-Activity Studies of Glucagon-like Peptide-1 (GLP-1),” J. Bio Chem 269(9):6275-8 (1994).
Bartlett, et al., “Inhibition of Chrymotrypsin by Phisphonate and Phosphonamidate Peptide Analogs,” Bioorg.Chem. 14:356-377 (1986).
Bhavsar, “Inhibition of Gastric Emptying and of Food Intake Appear to be Independently Controlled in Rodents,” Soc. Neurosci. Abst. 21:460 (188.8)(1995).
D'Alessio et al., “Elimination of the Action of Glucagon-like Peptide-1 Causes an Impairment of Glucose Tolerance After Nutrient Ingestion by Healthy Baboons,” J. Clin. Invest.
Eissele et al. “Rat Gastric Somatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-like Peptide-1 (GLP-1) Amide,” Life Sci., 55:629-34, (1994).
Eng et al. “Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from Heloderma suspectum Venom”, J. Biol. Chem., 267:7402-05, (1992).
Eng et al. “Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated from Heloderma horridum Venom,” J. Biol. Chem., 265:20259-62, (1990).
Fehmann et al., “Stable Expression of the Rat GLP-1 Receptor in CHO Cells: Activation and Binding Characteristics Utilizing CLP-1 (7-36)-Amide, Oxyntomodulin, Exendin-4, and Exending (9-39),”Peptides 15(3): 453-6, (1994).
Ferguson et al. “Cell-Surface Anchoring of Proteins via Glycosylphosphatidylinositol Structures”, Annu. Rev. Biochem. 57:285-320.
Goke, et al., “Exendin-4 is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-screening β-Cells”, J. Biol. Chem., 268:19650-55, (1993).
Goldstone, et al., “Leptin Interacts with GLucagon-like Peptide-1 Neutron to Reduce Food Intake and Body Weight in Rodents,” FEBS Letters, 415:134-138, (1997).
Halaas, J. L., et al., “Weight-Reducing Effects of the Plasma Protein Encoded by the Obese Gene,” Science 269:543-546, (1995).
Kodama, J., et al. “Effect of Captopril on Gluclose Concentration Possible Role of Augmented Postprandial Forearm Blood Flow,” Diabetes Care 13(11):1109-1111, (1990).
Kolligs, et al. “Reduction of the Incretin Effect in Rats by the Glucagon-like Peptide-1 Receptor Antagonist Exendin (9-39) Amide,” Diabetes 44:16-19, (1995).
Lawler, R.L., et al. “Comparison of Effects of Amylin,Glucagon-like Peptide-1 (GLP-1) and Exendin-4 to Inhibit Pentagastrin-stimulated Gastric Acid Secretion in Rats”; Gastroenterology, Saunders, Phildelphia,PA, US; vol. 112, No. 4-Suppl.,1997, p. A194; XP002167251—Abstract.
Leibel, R.L., et al., Changes in Energy Expenditures Resulting from Altered Body Weight, New England Journal of Medicine, 332 (10):621-628, (1995).
Lithell, et al., “Insulin Senstivity in Newly Detected Hypertensive Patients: Influence of Captopril and Other Antihypertensive Agents on Insulin Sensitivity and Related Biological Parameters,” J. Cardovasc. Pharmacol. 15 (Supp 5): S46-S52, (1990).
Malhotra, et al., “Exendin-4, A New Peptide fromn Heloderma suspectum Venom, Potentiates Cholecystrokimin-induced Amylase Release from Rat Pancreatic Acini”, Regulatory Peptide, 41: 149-56, (1992).
Montrose-Rafizadeh, et al., “Structure-function Analysis of Exendin-4/GLP-1 Analogs”, Diabetes, 45 (Suppl. 2): 152A, (1996).
Navarro, M. et al., “Colocalization of Glucagon-Like Peptide-1 (GLP-1) Receptors, Glucose Transporter GLUT-2, and Glucokinase mRNAs in Rat Hypothalamic Cells: Evidence for a Role of GLP-1 Receptor Agonists as an Inhibitory Signal for Food and Water Intake,” Journal of Neurochemistry. 67: 1982-1991, (1996).
O'Halloran et al., “Glucagon-like Peptide-1 (7-36)-NH2: a Physiological Inhibitor of Gastric Acid Secretion in Man,” J. Endocrinol 126 (1): 169-73, (1990).
Orskov, et al. “Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and Glucagonlike Peptide-1 7-37 in Healthy Subjects are Indistinguishable,” Diabetes, 42: 658-61, (1993).
Pelleymounter, et al., “Effects of the Obese Gene Product on Body Weight Regulation in OB/OB Mice,” Science 269: 540-43, (1995).
Raufman, et al. “Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Pig Pancreas,” J. Biol. Chem. 267: 21432-37, (1992).
Raufman, et al. “Exendin-3, a Novel Peptide from Heloderma horridum Venom, Interacts with Vasoactive Intestinal Peptide Receptros and a Newly Described Receptor on Dispersed Acini from Guinea Pig Pancreas,” J. Biol. Chem., 266: 2897-902, (1991).
Schepp, et al., “Exendin-4 and Exendin-(9-39) NH2: Agonist and Antagonist respectively, at the Rat Parietal Cell Receptor for Glucagon-like Peptide-1-(7-36) NH2,” Eur. J. Pharm, 269: 183-91, (1994).
Schjoldager, et al. “GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans,” Dig. Dis Sci 34 (5): 703-8, (1989).
Singh, et al. “Use of 1-[Y] Exendin-4 to Characterize Exendin Receptors on Dispersed Pancreatic Acini and Gastric Chief from Guinea Pig,” Regul. Pept. 53: 47-59, (1994).
Thorens, “Expression Cloning of the Pancreatic Cell Receptor for the Glucoincretin Hormone Glucagon-like Peptide 1,” Proc. Natl. Acad. Sci. USA 89: 8641-45, (1992).
Thorens, et al. “Cloning and Functional Expression of the Human Islet GLP-1 Receptor,” Diabetes 42 (11): 1678-82, (1993).
Turton, et al., “A Role for Glucagon-like Peptide-1 in the Central Regulation of Feeding,” Nature 379:69-72, (1996).
Veale, P.R., et al., “The Presence of Islet Amyloid Polypeptide/Calcitonin Gen-related Peptide/Salmon Calcitronin Binding Sites in the Rat Nucleaus Accumbens,” European Journal of Pharmacology 262:133-141, (1994).
Wang, et al. “Glucagon-like Peptide-1 Is a Physiological Incretin in Rat,” J. Clin. Invest., 95:417-21, (1995).
Watson, N.,, et al., “Effects of Captop

Affiliated with

Also associated with

Rating

Exendin agonist compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Exendin agonist compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Exendin agonist compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4177554